Michael King

Mike is an award-winning research analyst with over 25 years of experience advising company executives, determining fair value of companies, and creating outstanding relationships with buy-side investors, sell-side peers, and thought leaders in a variety of scientific and medical disciplines in the investment banking industry. In 2014, he was ranked first among all stock pickers in the pharmaceuticals category in the annual “Best on the Street” analyst survey conducted by The Wall Street Journal.

Prior to joining EF Hutton, Michael was a Managing Director and Senior Biotechnology Analyst at HC Wainwright & Co., LLC where he was responsible for initiating coverage of companies in the biotechnology space. Mike has held numerous leadership roles in biotechnology and healthcare research, including Entrepreneur in Residence at Fortress Biotech, Inc.; Managing Director and Senior Biotechnology Research Analyst at JMP Securities; Director of Research and Senior Biotechnology Analyst at Dawson James Securities; Managing Director and Senior Research Analyst at Rodman & Renshaw; Senior Vice President and Director of Corporate Development at publicly traded ZIOPHARM Oncology; and Managing Director and Senior Equity Analyst at Wedbush Securities. Additionally, he’s held research roles at Merriman Curhan Ford, Banc of America Securities, Robertson Stephens, Vector Securities and Dillon Read & Co., covering a wide range of market capitalizations and therapeutic categories.